Waverley Pharma Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Larry Thiessen

Chief Executive Officer (CEO)

CA$45.0k

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	4.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Larry Thiessen en comparación con los beneficios de Waverley Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-CA$2m
Mar 31 2024	n/a	n/a	-CA$2m
Dec 31 2023	CA$45k	CA$45k	-CA$2m
Sep 30 2023	n/a	n/a	-CA$1m
Jun 30 2023	n/a	n/a	-CA$910k
Mar 31 2023	n/a	n/a	-CA$693k
Dec 31 2022	CA$45k	CA$45k	-CA$664k
Sep 30 2022	n/a	n/a	-CA$725k
Jun 30 2022	n/a	n/a	-CA$810k
Mar 31 2022	n/a	n/a	-CA$934k
Dec 31 2021	CA$45k	CA$45k	-CA$797k
Sep 30 2021	n/a	n/a	-CA$851k
Jun 30 2021	n/a	n/a	-CA$642k
Mar 31 2021	n/a	n/a	-CA$697k
Dec 31 2020	CA$33k	CA$33k	-CA$706k

Compensación vs. Mercado: La compensación total de Larry($USD32.19K) está por debajo de la media de empresas de tamaño similar en el mercado Canadian ($USD169.13K).

Compensación vs. Ingresos: La compensación de Larry ha sido consistente con los resultados de la empresa en el último año.

CEO

Larry Thiessen

4.8yrs

Permanencia

CA$45,000

Compensación

Mr. Larry Thiessen MBA, serves as President and Chief Executive Officer at Waverley Pharma Inc. since February 1, 2020 and also serves as its Director since November 22, 2023. He has extensive pharmaceutic...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Larry Thiessen	President	less than a year	CA$45.00k	sin datos
Albert Friesen	Chairman of the Board	7.9yrs	sin datos	74.61% CA$ 604.4k
P. Enns	Independent Director	7.9yrs	sin datos	0.19% CA$ 1.5k
James Kinley	Director	less than a year	sin datos	0.10% CA$ 847.5

4.5yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de WAVE se considera experimentada (4.5 años de antigüedad promedio).

Waverley Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Waverley Pharma Inc. Elects James Kinley as Director

Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Waverley Pharma Inc. Announces Changes to Board of Directors

Recent updates

Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.

First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)

Waverley Pharma Inc. Elects James Kinley as Director

First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)

Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Waverley Pharma Inc. Announces Changes to Board of Directors

Waverley Pharma Inc. Announces Changes to Board of Directors

Insufficient new directors

Insufficient new directors

Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)

Insufficient new directors

Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)

Insufficient new directors

Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor Program

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)

Insufficient new directors

Insufficient new directors

First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)

Insufficient new directors

Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022

Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)

Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United States

First half earnings released

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad